Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1997-12-12
|
pubmed:abstractText |
The aim of this study was to evaluate the feasibility, toxicity and efficacy of escalating doses of subcutaneous recombinant interleukin-6 (IL-6) in children with solid tumours in relapse. Recombinant IL-6 was administered subcutaneously once daily for 14 consecutive days, with a 14 day follow-up period. The starting dose for IL-6 was 1 microgram/kg/day and was escalated in subsequent patients groups until 10 micrograms/kg. Doses were escalated every 3 patients, provided that grade III or IV organ toxicity did not occur at the preceding dose level. Twelve patients were treated, three at each dose level. No grade 3-4 major organ toxicity was observed. Flu-like symptoms and fatigue were the most common side effects. All these symptoms resolved after the end of IL-6 administration. Significant increases in acute-phase proteins (CRP [C reactive protein], fibrinogen) and ESR (Erthrocyte sedimentation rate) were observed in all patients. Stimulatory effects on thrombocytopoiesis were observed at every dose level, and were maximal at 5 micrograms/kg and 10 microgram/kg. There was no tumour response observed during IL-6 administration. Pharmacokinetic profiles performed in 3 patients are consistent with previous reports in adults. IL-6 is a promising new cytokine for paediatric oncology, in particular to increase thrombocyte counts. We recommend that further studies in children proceed at a dose of 5-10 micrograms/kg/day in a once or, better, twice daily administration.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
33
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1620-6
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9389924-Acute-Phase Proteins,
pubmed-meshheading:9389924-Adolescent,
pubmed-meshheading:9389924-Child,
pubmed-meshheading:9389924-Child, Preschool,
pubmed-meshheading:9389924-Dose-Response Relationship, Immunologic,
pubmed-meshheading:9389924-Feasibility Studies,
pubmed-meshheading:9389924-Female,
pubmed-meshheading:9389924-Humans,
pubmed-meshheading:9389924-Interleukin-6,
pubmed-meshheading:9389924-Male,
pubmed-meshheading:9389924-Neoplasms,
pubmed-meshheading:9389924-Platelet Count,
pubmed-meshheading:9389924-Recombinant Proteins
|
pubmed:year |
1997
|
pubmed:articleTitle |
Phase I study of interleukin-6 in children with solid tumours in relapse.
|
pubmed:affiliation |
Service de Pédiatrie, Centre Léon Bérard, Lyon, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|